

Analysis of innovative reimbursement submissions admitted on 1st of January 2022

Newsletter Special edition, Issue XIV. 2022 Published: 09/03/2022


Indications


Brands

Submissions

Our special edition focuses on those new, mainly innovative pharmaceutical technologies, which were admitted to the reimbursement system on 1st of January 2022. In case published by NHIFA.


After the change of legislation in 2018, the analysis of a submission's timeline faces many obstacles, since these procedures have to be closed within 360 days. In the case of submissions that appear to exceed this procedure time, companies tend to initiate the closure of the process and resubmitting the dossiers without any, or with minimal changes. In our analysis, the requests closed by a termination order and submitted again within a few






Average of days passed from submission to admission by companies (brands)

38





Actual timelines of ongoing procedures are the following

Astra

Zeneca

3/4

Janssen

2/4

Top 4 applicants by the number of brands

MSD

2/5

Novartis

3/5

max. 23)

Top 3 ATC main group by the number of

В

4/4

L - Antineop. & immonomo.: B - Blood.: N - Nervus system


N

1/2

L

18/23

Insurance - in line with the TÉB decision -, based on 2006. Act XCVIII. [Gyftv.], according to which reimbursement of pharmaceutical applications or alteration of reimbursement conditions of an already reimbursed medicine requires amendment of legislation



-mail to iroda@health